HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AREDS2

This article was originally published in The Tan Sheet

Executive Summary

Nearly 100 centers working on an NIH study on the effects of antioxidants and fish oil on progression of age-related macular degeneration seek 4,000 people ages 50 to 85 with AMD to participate, according to an Oct. 12 announcement. The National Eye Institute, which says nearly 2 mil. people in the U.S. suffer from vision loss due to advanced AMD and 7 mil. with AMD are at "substantial risk," expects the Age-Related Eye Disease Study 2 (AREDS2) to build upon results from the first AREDS data released in 2001 (1"The Tan Sheet" Oct. 15, 2001, p. 3). Those results showed high-dose antioxidant vitamins and minerals (vitamins C and E, beta-carotene, zinc, and copper) reduced the risk of progression to advanced AMD by 25%, and the risk of moderate vision loss by 19%. Results of a separate study published this year showed higher intake of omega-3 fatty acids could have prevented an estimated 22% of the cases of AMD (2"The Tan Sheet" July 17, 2006, p 9). DSM will supply the supplements for AREDS2...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel